JPWO2020041300A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020041300A5 JPWO2020041300A5 JP2021509746A JP2021509746A JPWO2020041300A5 JP WO2020041300 A5 JPWO2020041300 A5 JP WO2020041300A5 JP 2021509746 A JP2021509746 A JP 2021509746A JP 2021509746 A JP2021509746 A JP 2021509746A JP WO2020041300 A5 JPWO2020041300 A5 JP WO2020041300A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- cdr2
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 390
- 239000011230 binding agent Substances 0.000 claims description 141
- 238000000034 method Methods 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 8
- 210000000822 natural killer cell Anatomy 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 4
- 230000001629 suppression Effects 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 230000001965 increasing effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000004614 tumor growth Effects 0.000 claims description 3
- 101000945493 Homo sapiens Killer cell immunoglobulin-like receptor 3DL3 Proteins 0.000 claims description 2
- 101000764622 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 2 Proteins 0.000 claims description 2
- 102100034834 Killer cell immunoglobulin-like receptor 3DL3 Human genes 0.000 claims description 2
- 230000024932 T cell mediated immunity Effects 0.000 claims description 2
- 102100026224 Transmembrane and immunoglobulin domain-containing protein 2 Human genes 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 230000005907 cancer growth Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862720708P | 2018-08-21 | 2018-08-21 | |
| US62/720,708 | 2018-08-21 | ||
| PCT/US2019/047250 WO2020041300A1 (en) | 2018-08-21 | 2019-08-20 | B7-h7-binding agents and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021533796A JP2021533796A (ja) | 2021-12-09 |
| JP2021533796A5 JP2021533796A5 (https=) | 2022-08-29 |
| JPWO2020041300A5 true JPWO2020041300A5 (https=) | 2022-08-29 |
Family
ID=67841214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021509746A Pending JP2021533796A (ja) | 2018-08-21 | 2019-08-20 | Ｂ７−ｈ７結合剤及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210198366A1 (https=) |
| EP (1) | EP3850009A1 (https=) |
| JP (1) | JP2021533796A (https=) |
| CN (1) | CN112930357A (https=) |
| AU (1) | AU2019326438A1 (https=) |
| CA (1) | CA3108905A1 (https=) |
| WO (1) | WO2020041300A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110760483B (zh) * | 2019-11-08 | 2021-06-22 | 扬州大学 | 具牛、羊交叉反应的抗TNF-α单克隆抗体的制备及应用 |
| WO2023138579A1 (zh) * | 2022-01-21 | 2023-07-27 | 和铂医药美国股份有限公司 | 抗b7-h7抗体或其抗原结合片段及制备方法和应用 |
| WO2023173393A1 (zh) * | 2022-03-18 | 2023-09-21 | 北京天广实生物技术股份有限公司 | 结合b7-h3的抗体及其用途 |
| WO2025040144A1 (zh) * | 2023-08-23 | 2025-02-27 | 南京再明医药有限公司 | B7-h7抗原结合分子及其应用 |
| CN119841949A (zh) * | 2023-10-17 | 2025-04-18 | 科辉智药(深圳)新药研究中心有限公司 | 一种抗人hhla2的纳米抗体及其应用 |
| WO2025111382A2 (en) * | 2023-11-21 | 2025-05-30 | Board Of Regents, The University Of Texas System | Anti-lamp5 antibodies, engineered immune cells expressing anti-lamp5 antibodies, and uses thereof |
| WO2025175056A1 (en) * | 2024-02-15 | 2025-08-21 | Nextpoint Therapeutics, Inc. | Multispecific antibodies or antigen binding fragments thereof to b7-h7 and immune effector cell antigens |
| CN121005781A (zh) * | 2024-05-24 | 2025-11-25 | 合肥天港免疫药物有限公司 | 高亲和力b7h7抗体或其抗原结合片段及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2666152T3 (es) * | 2009-08-13 | 2018-05-03 | The Johns Hopkins University | Métodos de modulación de la función inmunitaria con anticuerpos anti-B7-H7CR |
| WO2014133728A2 (en) * | 2013-03-01 | 2014-09-04 | Albert Einstein College Of Medicine Of Yeshiva University | Hhla2 as a novel inhibitor of human immune system and uses thereof |
| WO2015187359A1 (en) * | 2014-06-04 | 2015-12-10 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for targeting a pathway |
-
2019
- 2019-08-20 EP EP19762577.5A patent/EP3850009A1/en not_active Withdrawn
- 2019-08-20 CN CN201980067874.XA patent/CN112930357A/zh active Pending
- 2019-08-20 AU AU2019326438A patent/AU2019326438A1/en not_active Abandoned
- 2019-08-20 US US17/269,635 patent/US20210198366A1/en not_active Abandoned
- 2019-08-20 JP JP2021509746A patent/JP2021533796A/ja active Pending
- 2019-08-20 WO PCT/US2019/047250 patent/WO2020041300A1/en not_active Ceased
- 2019-08-20 CA CA3108905A patent/CA3108905A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| AU2020324183B2 (en) | Anti-TNFR2 antibody and use thereof | |
| JP2021533796A5 (https=) | ||
| RU2018114523A (ru) | Анти-tigit антитела и способы применения | |
| JP2021508469A5 (https=) | ||
| RU2018126297A (ru) | Антитела, нацеленные на cd32b, и способы их применения | |
| JPWO2019129221A5 (https=) | ||
| JP2018533371A5 (https=) | ||
| JP2020510422A5 (https=) | ||
| RU2017142008A (ru) | Новые полипептиды | |
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| EP3645741A2 (en) | Anti-4-1bb antibodies and methods of making and using thereof | |
| JP2018503380A5 (https=) | ||
| JP2018519364A5 (https=) | ||
| JP2021510521A5 (https=) | ||
| JP2018503365A5 (https=) | ||
| JPWO2021011885A5 (https=) | ||
| RU2012113554A (ru) | Антитела к рецепту глюкагана и их использование | |
| JP2021520201A5 (https=) | ||
| CN112292399A (zh) | 抗cd27抗体及其用途 | |
| JP2021520195A5 (https=) | ||
| JP2021523949A5 (https=) | ||
| JP2023524238A (ja) | 治療用ＳＩＲＰα抗体 | |
| CN111886023A (zh) | 针对tim-3的抗体及其用途 | |
| CN114790241B (zh) | 抗tigit抗体及其应用 |